Table 3.
Detection limits of the Discovery assay
| Cytokine | Samples within standard curvea | Cytokine | Samples within standard curvea | Cytokine | Samples within standard curvea |
|---|---|---|---|---|---|
| BCA-1 | 47/47 (100%) | IL-6 | 43/47 (91%) | MCP-3 | 20/47 (43%) |
| CTACK | 47/47 (100%) | IL-7 | 26/47 (55%) | MCP-4 | 46/47 (98%) |
| EGF | 38/47 (81%) | IL-8 | 39/47 (83%) | MDC | 47/47 (100%) |
| ENA-78 | 47/47 (100%) | IL-9 | 47/47 (100%) | MIP-1α | 34/47 (72%) |
| Eotaxin-1 | 47/47 (100%) | IL-10 | 42/47 (89%) | MIP-1β | 44/47 (94%) |
| Eotaxin-2 | 45/47 (96%) | IL-12P40 | 27/47 (57%) | MIP-1d | 47/47 (100%) |
| Eotaxin-3 | 47/47 (100%) | IL-12P70 | 41/47 (87%) | PDGF-AA | 47/47 (100%) |
| FGF-2 | 47/47 (100%) | IL-13 | 22/47 (47%) | PDGF-BB | 46/47 (98%) |
| Flt-3 Ligand | 20/47 (43%) | IL-15 | 46/47 (98%) | RANTES | 37/47 (79%) |
| Fractalkine | 42/47 (89%) | IL-16 | 47/47 (100%) | sCD40L | 47/47 (100%) |
| G-CSF | 40/47 (85%) | IL-17A | 39/47 (83%) | SCF | 20/47 (43%) |
| GM-CSF | 40/47 (85%) | IL-18 | 43/47 (91%) | SDF-1 | 46/47 (98%) |
| GRO pan | 45/47 (96%) | IL-20 | 45/47 (96%) | TARC | 47/47 (100%) |
| IFNα2 | 42/47 (89%) | IL-21 | 22/47 (47%) | TGF-a | 36/47 (77%) |
| IFNγ | 36/47 (77%) | IL-23 | 45/47 (96%) | TNFα | 47/47 (100%) |
| IL-1α | 46/47 (98%) | IL-28A | 46/47 (98%) | TNFβ | 22/47 (47%) |
| IL-1B | 35/47 (74%) | IL-33 | 29/47 (62%) | TPO | 39/47 (83%) |
| IL-1RA | 40/47 (85%) | IP-10 | 47/47 (100%) | TRAIL | 47/47 (100%) |
| IL-2 | 28/47 (60%) | I-309 | 47/47 (100%) | TSLP | 42/47 (89%) |
| IL-3 | 47/47 (100%) | LIF | 33/47 (70%) | VEGF-A | 32/47 (68%) |
| IL-4 | 19/47 (40%) | MCP-1 | 47/47 (100%) | 6CKINE | 47/47 (100%) |
| IL-5 | 36/47 (77%) | MCP-2 | 47/47 (100%) |
aPercentage of the 47 plasma samples with target protein fluorescence intensity values within the protein standard curve. Absolute cytokine concentration for 15/65 cytokines (shown in bold) could not be calculated in more than 75% of plasma samples because fluorescence intensity values were below the standard curve